CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CRL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CRL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRL
Charles River Laboratories International, Inc. is a non-clinical drug development services company providing outsourcing solutions across research models, discovery and safety assessment, and manufacturing, with a focus on strategic portfolio adjustments and cost optimization amid a challenging demand environment.
Key risk: High debt leverage
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 27, 2026.
Charles River Laboratories International, Inc. is a non-clinical drug development services company providing outsourcing solutions across research models, discovery and safety assessment, and manufacturing, with a focus on strategic portfolio adjustments and cost optimization amid a challenging demand environment.
- Cash and equivalents of $240.6M, total revenue of $1,004.1M, net loss of $1.5M, shareholders' equity of $3,353.3M, and total debt of $2,625.4M as of 2026-06-27 [sec].
- The company is executing planned divestitures of its CDMO and Cell Solutions businesses and certain European Discovery Services assets to IQVIA for ~$145M [sec · filed 2026-02-25].
- A restructuring program is expected to deliver approximately $225 million in annualized cost savings [sec · filed 2025-04-02].
- In April 2026, Charles River acquired an additional 79% equity interest in PathoQuest SAS for $67.6 million, reported in the Manufacturing segment [sec_mda · as of 2026-08-05].
What works
- The company holds a leadership position in non-clinical drug development and is leveraging its broad scientific capabilities and global scale to meet shifting client demand [sec · filed 2026-03-31].
- Strategic acquisitions and partnerships, such as the PathoQuest acquisition and Noveprim Group stake, are expanding the portfolio and securing supply chains [sec · filed 2025-04-02] [sec_mda · as of 2026-08-05].
- A cost optimization program targeting $225 million in annualized savings is underway to right-size the cost structure to the demand environment [sec · filed 2025-04-02].
- The company is investing in technology like the Apollo™ cloud platform to enhance client experience and enable self-service tools [sec · filed 2026-03-31].
What to weigh
- The company reported a net loss of $1.5M as of 2026-06-27, reflecting ongoing financial pressure [sec].
- Total debt of $2,625.4M significantly exceeds cash of $240.6M, indicating high leverage [sec].
- Client demand, particularly from global biopharma, is constrained due to restructuring programs and pipeline reprioritization, with DSA pricing expected to be a headwind [sec · filed 2025-01-14].
- The planned divestitures of CDMO and certain Discovery Services assets may reduce revenue scale and signal a narrowing of the business focus [sec · filed 2026-02-25].
From the filings
Quoted directly from source documents.
The company is divesting its CDMO and Cell Solutions businesses and certain European Discovery assets.
“planned divestitures of the contract development and manufacturing products and services (CDMO) and Cell Solutions businesses and certain European sites within the Discovery Services business.”
SEC filings · March 31, 2026
A restructuring program is expected to generate $225 million in annualized cost savings.
“will result in approximately $225 million of cost savings on an annualized basis.”
SEC filings · April 2, 2025
The company acquired an additional 79% equity interest in PathoQuest SAS for $67.6 million.
“On April 17, 2026, we completed the acquisition of an additional 79% equity interest in PathoQuest SAS (PathoQuest), for $67.6 million.”
SEC MD&A · August 5, 2026
Client demand from global biopharma is constrained due to restructuring and pipeline reprioritization.
“Constrained spending from global biopharma clients due to impact of restructuring programs and pipeline reprioritization efforts”
SEC filings · January 14, 2025
Risks & what to watch (4)›
Key risks
- High debt leverage — Total debt of $2,625.4M far exceeds cash of $240.6M, increasing financial risk [sec].
- Net loss reported — Net loss of $1.5M as of 2026-06-27 indicates profitability challenges [sec].
- Demand headwinds from biopharma — Constrained spending from global biopharma clients due to restructuring and pipeline reprioritization [sec · filed 2025-01-14].
- Divestiture execution risk — Planned divestitures of CDMO and Discovery assets may face closing conditions or integration issues [sec · filed 2026-02-25].
What to watch
- Progress and closing of the divestiture of CDMO and Cell Solutions businesses and European Discovery assets to IQVIA [sec · filed 2026-02-25].
- Realization of $225 million in annualized cost savings from the restructuring program [sec · filed 2025-04-02].
- Trends in DSA client demand and pricing, especially from global biopharma and biotech clients [sec · filed 2025-01-14].
- Integration and financial impact of the PathoQuest acquisition on the Manufacturing segment [sec_mda · as of 2026-08-05].
Sources: SEC filings · SEC MD&A · Generated August 24, 2026 · How we verify sources →
Run CHARLES RIVER LABORATORIES INTERNATIONAL, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CHARLES RIVER LABORATORIES INTERNATIONAL, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
8.2 months
D/E 1.64 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
1 buy · 17 sells (180d)
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
557
Total value held
$9.23B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 6,404,408 | $1.10B |
| blackrock, inc. | 3,859,100 | $665.7M |
| fmr llc | 3,456,244 | $596.2M |
| vanguard portfolio management llc | 2,294,670 | $395.8M |
| harris associates l p | 2,153,296 | $371.4M |
| state street corp | 1,873,618 | $323.2M |
| dimensional fund advisors lp | 1,652,484 | $285.0M |
| wellington management group llp | 1,629,401 | $281.1M |
| ariel investments, llc | 1,444,183 | $249.1M |
| geode capital management, llc | 1,305,694 | $224.8M |
Showing top 10 of 557 institutional holders of CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 8.0%
- Days to cover
- 4.1
- Shares short
- 3,349,211
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRL short interestGovernance
Frequently asked questions
What is the AI investment thesis for CHARLES RIVER LABORATORIES INTERNATIONAL, INC.?
Charles River Laboratories International, Inc. is a non-clinical drug development services company providing outsourcing solutions across research models, discovery and safety assessment, and manufacturing, with a focus on strategic portfolio adjustments and cost optimization amid a challenging demand environment.
Who is the CEO of CHARLES RIVER LABORATORIES INTERNATIONAL, INC.?
Ms. Birgit Girshick is the chief executive officer of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL).
Where is CHARLES RIVER LABORATORIES INTERNATIONAL, INC. headquartered?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is headquartered in Wilmington, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.